Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) – Pipeline Review, H2 2017’, provides in depth analysis on Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advaxis Inc

Aeterna Zentaris Inc

Bavarian Nordic A/S

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Overview

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Companies Involved in Therapeutics Development

Advaxis Inc

Aeterna Zentaris Inc

Bavarian Nordic A/S

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Drug Profiles

ADXS-PSA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEZS-120 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA for Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-114 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-115 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5150 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonl Antibody to Inhibit PSA for Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostatac Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilimogene galvacirepvec Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Dormant Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Discontinued Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) Product Development Milestones

Featured News & Press Releases

Dec 21, 2017: One-Year Follow-Up Shows

71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial

Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up

Sep 19, 2017: Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer Meeting

Sep 14, 2017: Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer

Sep 14, 2017: OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer

Sep 11, 2017: Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress

Sep 11, 2017: Inovios Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer

Aug 31, 2017: OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment

Aug 29, 2017: OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference

Aug 24, 2017: Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer

Aug 02, 2017: Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Jul 13, 2017: Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement

Jun 27, 2017: Enrollment to Begin in OncBioMunes Trial of ProscaVax for Prostate Cancer in Mexico

Jun 21, 2017: OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Advaxis Inc, H2 2017

Pipeline by Aeterna Zentaris Inc, H2 2017

Pipeline by Bavarian Nordic A/S, H2 2017

Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Pipeline by Inspyr Therapeutics Inc, H2 2017

Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports